

Summary of the material ways in which the UK Corporate Governance Code, as applied by the Company, differs from the principles of the Swedish Code on Corporate Governance

AstraZeneca PLC (the "**Company**") is a public limited company incorporated in England and Wales. The Company's shares are listed on the New York Stock Exchange, London Stock Exchange and Nasdaq Stockholm Stock Exchange under a harmonised listing structure.

In accordance with the Company's listing on the London Stock Exchange the Company follows and generally complies with the UK Corporate Governance Code (the "**UK Code**") in respect of its corporate governance practices. The 2024 edition of the UK Code came into effect for reporting periods beginning on or after 1 January 2025, and was effective to the Company for the year ended 31 December 2025 (with Provision 29 becoming applicable from 1 January 2026). The Companies Act 2006 and the UK Listing Rules of the UK Financial Conduct Authority impose certain requirements that also influence the Company's corporate governance practices. As a result of its listing on Nasdaq Stockholm Stock Exchange and, as a foreign issuer, the Company is permitted to follow the corporate governance practice of its home country in lieu of the Swedish Corporate Governance Code (the "**Swedish Code**").

This document sets out the material ways in which the Company's corporate governance practices differ from the Swedish Code. The Company is required to disclose the material ways in which its corporate governance practices differ from the Swedish Code. The Company has reviewed the corporate governance practices required to be followed under the Swedish Code and its corporate governance practices are generally consistent with those standards, save as set out below and save where divergencies are the result of differences in the structure of companies incorporated in the UK versus companies incorporated in Sweden.

The Swedish Code	AstraZeneca Corporate Governance Practice
<p>Under the Swedish Code, the Nomination Committee is a shareholders' committee that is responsible for proposing, <i>inter alia</i>, candidates for the position of Board member and Chair of the Board. In addition, the shareholders' meeting is to appoint members of the Nomination Committee or to specify how they are to be appointed. The shareholders' meeting is to provide written instructions to the Nomination Committee.</p>	<p>Under the UK Code, members of the Nomination Committee are appointed by the Board and a majority of the members of the Company's Nomination Committee should be independent non-executive directors.</p> <p>AstraZeneca's Nomination and Governance Committee Terms of Reference are available on the Company's website.</p>
<p>Under the Swedish Code, the Nomination Committee is responsible for proposing the election and remuneration of the statutory auditor after recommendation from the audit committee.</p>	<p>Under the UK Code, the Nomination Committee does not have any role in the election and remuneration of the auditor; this is done by the Audit Committee.</p> <p>More detail on the work of AstraZeneca's Audit Committee can be found in the Audit Committee Report on pages 83 to 89 of the Company's Annual Report for the year ended 31 December 2025.</p>

Under the Swedish Code, the Nomination Committee is to have at least three members, one of whom is to be appointed committee chair. In addition, the majority of the members of the Nomination Committee are to be independent of the Company and its executive management. Neither the chief executive officer nor other members of the executive management are to be members of the Nomination Committee and Board members may not constitute a majority thereof. At least one member of the Nomination Committee is to be independent of the Company's largest shareholder in terms of votes or any group of shareholders who act in concert in the governance of the Company.

Under the UK Code, there is no requirement as to the number of members the Nomination Committee should have. The chief executive officer and other members of executive management may be members of the Nomination Committee, provided that a majority of members of the committee are independent non-executive directors (and independent non-executive directors cannot be connected to major shareholders). There are no restrictions on the Company's chair or other Board members chairing the Nomination Committee, except that the chair of the Board may not chair the Nomination Committee when it is dealing with the appointment of their successor.

AstraZeneca's Nomination and Governance Committee Terms of Reference are available on the Company's website.